Perrigo

{{Infobox company

| name = Perrigo Company plc

| former_name = Perrigo Inc. (before the 2013 tax inversion to Ireland)

| logo = Perrigo logo.svg

| ISIN = {{ISIN|sl=n|pl=y|IE00BGH1M568}}

| image =

| type = Public

| traded_as = {{ubl|{{NYSE|PRGO}}|S&P 400 component}}

| founded = {{start date and age|df=yes|1887}} as L. Perrigo Company in Allegan, Michigan, U.S.

| founders = {{nowrap| Luther and Charles Perrigo}}

| hq_location = * Dublin, Ireland (legal)

Grand Rapids, Michigan, U.S. (operational)

| key_people = Patrick Lockwood-Taylor (President and CEO)

| industry = Pharmaceutical

| products = {{ubl|OTC|RX|API|Medical Diagnostics|Pharmaceuticals}}

| revenue = {{decrease}} {{US$|4.37 billion|link=yes}} (2024)

| operating_income = {{decrease}} US$113 million (2024)

| net_income = {{decrease}} US$−172 million (2024)

| assets = {{decrease}} US$9.65 billion (2024)

| equity = {{decrease}} US$4.32 billion (2024)

| num_employees = 8,379 (2024)

| subsid = {{unbulleted list|Omega Pharma}}

| website = {{URL|perrigo.com}}

| footnotes = {{cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1585364/000158536425000014/prgo-20241231.htm |title=Perrigo Company plc 2024 Annual Report (Form 10-K) |date=2025-02-28 |publisher=U.S. Securities and Exchange Commission}}

}}

Perrigo Company plc ({{langx|he|פריגו}}) is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales.{{cite book|title=Perrigo Co plc: Form 10-Q (29 September 2018)|date=8 November 2018|publisher=Securities and Exchange Commission|quote=Disaggregation of Revenue|page=9}}{{Cite news|last=Automation|first=MarketWatch|title=Perrigo Co. PLC stock rises Wednesday, still underperforms market|url=https://www.marketwatch.com/story/perrigo-co-plc-stock-rises-wednesday-still-underperforms-market-01626902214-1b48307404aa|access-date=2021-07-22|website=MarketWatch|language=EN-US}} In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.{{Cite web |last=McVicar |first=Brian |date=2022-06-30 |title=Perrigo unveils new North American Corporate Headquarters on Grand Rapids' Medical Mile |url=https://www.mlive.com/news/grand-rapids/2022/06/perrigo-unveils-new-north-american-corporate-headquarters-on-grand-rapids-medical-mile.html |access-date=2022-10-27 |website=mlive |language=en}}

Perrigo engages in the acquisition (for repricing), manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients (APIs), primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.{{cite web|url=https://www.irishtimes.com/business/health-pharma/the-terrible-irony-of-perrigo-s-tax-planning-1.3739781|title=The terrible irony of Perrigo's tax planning|publisher=Irish Times|author=Cantillion|date=21 December 2018}}{{cite web|url=https://www.wsj.com/articles/perrigo-tax-shocker-couldnt-come-at-worse-time-11545408948|title=Perrigo Tax Shocker Couldn't Come at Worse Time|publisher=Wall Street Journal|author=Charly Grant|date=21 December 2018}}

History

L. Perrigo Company was founded in 1887 in Allegan, Michigan, by Luther and Charles Perrigo, who ran a general store.{{Citation | title = Perrigo Company - Company History | url = http://www.fundinguniverse.com/company-histories/Perrigo-Company-Company-History.html | journal = Funding Universe | access-date = 2009-10-31}}

In 1991 Perrigo had an initial public offering on Nasdaq.{{Cite news |last=Walsh |first=Tom |date=2015-08-29 |title=Perrigo's growth makes it a tempting target |url=https://www.freep.com/story/money/2015/08/28/perrigo-fights-takeover/71331478/ |work=Detroit Free Press}}{{Cite web |url=https://www.finra.org/rules-guidance/notices/92-7 |title=Nasdaq National Market Additions, Changes, and Deletions as of December 19, 1991 |date=1992-01-01 |publisher=Financial Industry Regulatory Authority}}

In March 2005 the firm acquired Agis Industries Limited (traded as AGIS at the Tel Aviv Stock Exchange), an Israel-based generic pharmaceuticals company in an $850 million transaction. Agis was founded in 1983 by Mori Arkin, who developed his father's small drug import business into a multinational generic pharmaceutical company. As a result of the acquisition, Arkin owned 9% of Perrigo, and was appointed as Vice Chairman of the company.{{cite press release | title = Perrigo Company to Acquire Agis Industries, Creating A Leading Diversified Healthcare Company | url = http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/news_ir_114.11.15%20Perrigo%20to%20Acquire%20Agis.pdf | publisher = Company press release | access-date = 31 October 2009 | archive-url = https://web.archive.org/web/20061025235552/http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/news_ir_114.11.15%20Perrigo%20to%20Acquire%20Agis.pdf | archive-date = 25 October 2006 | url-status = dead | df = dmy-all }}

In July 2013, Perrigo announced that it would execute a corporate tax inversion to Ireland in order to avoid U.S. corporate taxes, via an $8.6 billion acquisition of Irish-based Elan Corporation.{{cite web| url=https://www.reuters.com/article/elan/update-4-u-s-drugmaker-perrigo-to-buy-irelands-elan-for-8-6-bln-idUSL6N0FZ0MY20130729|title=UPDATE 4-U.S. drugmaker Perrigo to buy Ireland's Elan for $8.6 bln|date=29 July 2013|publisher=Reuters|quote=DUBLIN, July 29, 2013 (Reuters) - U.S. drugmaker Perrigo agreed to buy Elan for $8.6 billion in a deal that will hand it tax savings from being domiciled in Ireland and royalties from a blockbuster multiple sclerosis treatment.}} {{As of| November 2018}}, Perrigo is the sixth-largest U.S. tax inversion in history.{{cite web|url=https://www.thestreet.com/slideshow/14222919/1/as-treasury-moves-to-bring-back-inversions-here-are-seven-of-the-biggest-recent-deals.html|title=As Treasury Moves to Bring Back Inversions, Here are 7 of the Biggest Recent Deals|author=Emily Stewart|date=22 July 2017|publisher=TheStreet}}{{cite news|url=https://www.washingtonpost.com/news/wonk/wp/2014/08/06/these-are-the-companies-abandoning-the-u-s-to-dodge-taxes/?noredirect=on|title=These are the companies abandoning the U.S. to dodge taxes|date=6 August 2014|newspaper=The Washington Post|author=Danielle Douglas-Gabriel}}{{cite news|url=https://www.bloomberg.com/graphics/tax-inversion-tracker/|title=Tracking Tax Runaways|newspaper=Bloomberg.com|publisher=Bloomberg News|date=1 March 2017|quote=Bloomberg Special Reports: Corporate Tax Inversions}} Over 70% of Perrigo's sales, and an even greater percentage of Perrigo profits, are from the U.S. healthcare system.{{cite web|url=https://www.forbes.com/sites/janetnovack/2014/09/10/the-tax-inversion-rush-in-one-handy-graphic/#4b2eac18bf02|title=The Tax Inversion Rush: One Handy Graphic|work=Forbes Magazine|author=Janet Novack|date=10 September 2014|quote=The U.S. company is in black, as is the share of the merged company its current shareholders will own; it must be less than 80% for the tax trick to work under the current law.}}

In April 2015, Perrigo received an unsolicited buy-out offer from Mylan of $29 billion, which was ultimately rejected by management and shareholders.{{cite press release | publisher=Reuters| date=8 April 2015| title=Generic drugmaker Mylan offers $29 billion for Perrigo | url=https://www.reuters.com/article/us-perrigo-company-m-a-mylan-idUSKBN0MZ1OX20150408}} In May 2016, Perrigo investors sued the company over statements made during the Mylan bid,{{Cite web|url=https://www.bloombergindustry.com/|title=Bloomberg Industry Group|website=Bloomberg Industry}} which were said to have persuaded shareholders to vote against the deal.{{cite web|url=http://www.bizjournals.com/pittsburgh/news/2016/05/24/lawsuit-filed-against-former-mylan-acquisition.html|title=Lawsuit filed against former Mylan acquisition target Perrigo - Pittsburgh Business Times}}{{Cite web|url=https://www.law360.com/articles/818827/perrigo-investor-slams-co-over-mylan-s-failed-takeover|title=Perrigo Investor Slams Co. Over Mylan's Failed Takeover - Law360|website=www.law360.com}} In the months prior to this suit, the company's chairman and CEO, Joseph Papa, who has been credited with "fending off" Mylan's bid, left to take the CEO role at Valeant.{{Cite news|url=https://www.businessinsider.com/valeant-new-ceo-pay-package-2016-4|title=Now we know why Valeant's new CEO took the job, and it seems politicians are upset about it|last=Lopez|first=Linette|date=28 April 2016|work=Business Insider UK|access-date=13 March 2018}}{{Cite journal|last=Wright|first=Rob|date=9 January 2018|title=Can Joseph Papa Save Valeant?|url=https://www.lifescienceleader.com/doc/can-joseph-papa-save-valeant-0001|journal=Life Science Leader|url-access=limited|access-date=13 March 2018}} Upon Papa's departure, John Hendrickson, who was at the time the company's president, took on the additional roles of chairman and CEO.{{Cite news|url=https://www.fiercepharma.com/pharma/perrigo-ceo-hendrickson-to-depart-after-rocky-13-month-turn-at-top|title=Floundering Perrigo's CEO Hendrickson to depart after rocky 13-month tenure|last=Helfand|first=Carley|date=6 June 2017|work=FiercePharma|access-date=13 March 2018}}{{Cite news|url=http://www.ibtimes.com/valeant-joseph-papa-joins-pharmaceutical-company-chief-exec-perrigo-names-hendrickson-2359026|title=Valeant: Joseph Papa Joins Pharmaceutical Company As Chief Exec As Perrigo Names Hendrickson New CEO|last=|date=25 April 2016|work=International Business Times|access-date=13 March 2018}} Hendrickson was succeeded by Uwe Roehrhoff in January, 2018.{{cite news|url=https://www.reuters.com/article/us-perrigo-company-ceo-idUSKBN1EX0GR|title=Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO|newspaper=Reuters|date=8 January 2018|via=www.reuters.com}} Murray S. Kessler succeeded Roehroff already in October of that same year. As of July 2023, Patrick Lockwood-Taylor is the current President and CEO.{{cite web|url=https://investor.perrigo.com/2018-10-08-Perrigo-Appoints-Murray-S-Kessler-As-President-And-Chief-Executive-Officer-In-Line-With-Shift-To-Consumer-Focused-Strategy|title=Press Releases|website=Perrigo InvestorRoom}}

On 20 December 2018, the Financial Times reported that the Irish Revenue Commissioners levied a €1.64 billion (not including penalties and interest) Irish tax claim on Perrigo for unpaid capital gains tax (CGT) from the 2013 sale of Tysabri to Biogen by Elan, which happened months before Perrigo's acquisition of Elan.{{cite web|url=https://www.ft.com/content/c72affc0-04a4-11e9-99df-6183d3002ee1|title=Drugs group Perrigo hit with €1.64bn Irish back tax bill|date=20 December 2018|publisher=Financial Times|author=Authur Beesley|quote=The tax assessment is Ireland’s largest since the European Commission directed Apple to pay €14.3bn in disputed back taxes to Dublin in a record-breaking ruling that the Irish authorities have taken to the European courts for an appeal.}} The claim is the second largest ever issued by the Revenue Commissioners in Irish history, after Apple's €13 billion Irish tax fine. On 21 December 2018, the Irish Times reported that Revenue claimed Perrigo owed CGT at a rate of 33% as an "asset sale", however Perrigo claimed that the sale was part of Elan's normal "trading income", and was subject to the lower 12.5% Irish corporate tax rate, which Perrigo was able to reduce to 0% using Ireland's multinational tax BEPS tools.{{cite web|url=https://www.irishtimes.com/business/health-pharma/what-s-the-massive-perrigo-tax-bill-all-about-1.3739350|title=What's the massive Perrigo tax bill all about?|publisher=Irish Times|author=Cliff Taylor|date=21 December 2018|quote=A twist is that Elan used accumulated losses to avoid paying any up-front tax bill at the time on the initial payment from Biogen.}}

In June 2022, Perrigo moved its corporate headquarters from Allegan to downtown Grand Rapids, about 40 miles north, within Michigan State University's Grand Rapids Innovation Park. The company still maintains offices and production at the Allegan campus.

In 2023, its subsidiary, HRA Pharma, received approval from the FDA to sell an over the counter women’s contraception drug called Opill.{{cite web | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive | archive-url=https://web.archive.org/web/20230713130226/https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive | url-status=dead | archive-date=13 July 2023 | title=FDA Approves First Nonprescription Daily Oral Contraceptive | website=Food and Drug Administration | date=13 July 2023 }}

=Acquisitions=

On 9 January 2008, the firm acquired Galpharm Healthcare, Ltd., a supplier of over-the-counter store brand pharmaceuticals in the United Kingdom.{{Cite web |url=http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/PRGOPR(11).pdf |title=Archived copy |access-date=5 July 2011 |archive-url=https://web.archive.org/web/20111009135258/http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/PRGOPR(11).pdf |archive-date=9 October 2011 |url-status=dead |df=dmy-all }}{{Cite news|date=2008-01-09|title=Perrigo buys Galpharm Healthcare for $86 million|language=en|work=Reuters|url=https://www.reuters.com/article/perrigo-acquisition-idUSWNAS603120080109|access-date=2021-07-22}} On 16 September 2008, the firm acquired J.B. Laboratories.{{cite web |url=http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/JBLABPR.pdf |title=Official Perrigo Company Press Release |access-date=2012-03-13 |archive-url=https://web.archive.org/web/20101129152733/http://perrigo.com/uploadedFiles/Investors/Press_Releases/JBLABPR.pdf |archive-date=29 November 2010 |url-status=dead |df=dmy-all }} On 6 October 2008, it acquired Laboratorios Diba S.A., enabling the company to market its products in Mexico.{{cite web |url=http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/DIBAPR.pdf |title=Official Perrigo Company Press Release |access-date=2012-03-13 |archive-url=https://web.archive.org/web/20120314192028/http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/DIBAPR.pdf |archive-date=14 March 2012 |url-status=dead |df=dmy-all }} On 13 November 2008, it acquired Unico Holdings, a manufacturer of store brand pediatric electrolytes, enemas and feminine hygiene products for retail consumers in the U.S.{{cite web |url=http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/UNIPR.pdf |title=Archived copy |access-date=2011-07-05 |url-status=dead |archive-url=https://web.archive.org/web/20110623072008/http://perrigo.com/uploadedFiles/Investors/Press_Releases/UNIPR.pdf |archive-date=23 June 2011 |df=dmy-all }}

On 1 March 2010, the firm acquired Orion Laboratories Pty, Ltd., a supplier of over-the-counter (OTC) store brand pharmaceutical products in Australia and New Zealand.{{cite web |url=http://www.perrigo.com/uploadedfiles/Investors/Press_Releases/ORION.pdf |title=Archived copy |access-date=2011-07-05 |url-status=dead |archive-url=https://web.archive.org/web/20110715064939/http://www.perrigo.com/uploadedfiles/Investors/Press_Releases/ORION.pdf |archive-date=15 July 2011 |df=dmy-all }} On 23 March 2010, it acquired PBM Holdings, Inc., a producer of over-the-counter store brand infant formula and baby foods in the United States, Canada, Mexico and China.{{cite web |url=http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/PBMCLS.pdf |title=Archived copy |access-date=2011-07-05 |url-status=dead |archive-url=https://web.archive.org/web/20110623064940/http://perrigo.com/uploadedFiles/Investors/Press_Releases/PBMCLS.pdf |archive-date=23 June 2011 |df=dmy-all }}{{Cite web|title=Perrigo Closes Acquisition of Infant Formula Manufacturer PBM Holdings|url=https://fif.cnsmedia.com/a/GSz6CCPdBCs=|access-date=2021-07-22|website=.foodingredientsfirst.com/|language=en}}{{Cite web|date=2010-03-23|title=Allegan-based Perrigo to buy infant formula maker PBM Holdings in $808 million deal|url=https://www.mlive.com/business/west-michigan/2010/03/allegans_perrigo_to_buy_infant.html|access-date=2021-07-22|website=mlive|language=en}}{{Cite web|title=Perrigo Acquires Baby Food Maker PBM|url=https://storebrands.com/perrigo-acquires-baby-food-maker-pbm|access-date=2021-07-22|website=Store Brands|language=en}}

On 20 January 2011, the firm announced that it would acquire Paddock Laboratories Inc., with the deal expected to close in fiscal 2012.{{cite web |url=http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/110119%20Paddle%20PR%20v9%20-%20FINAL%20CHANGES.pdf |title=Archived copy |access-date=2011-07-05 |url-status=dead |archive-url=https://web.archive.org/web/20110626213156/http://www.perrigo.com/uploadedFiles/Investors/Press_Releases/110119%20Paddle%20PR%20v9%20-%20FINAL%20CHANGES.pdf |archive-date=26 June 2011 |df=dmy-all }}{{Cite web|date=2011-01-20|title=Perrigo Company to buy assets of Paddock Laboratories for $540m in cash|url=https://www.proactiveinvestors.com/companies/news/69039/perrigo-company-to-buy-assets-of-paddock-laboratories-for-540m-in-cash-11633.html|access-date=2021-07-22|website=Proactiveinvestors NA|language=en}}{{Cite web|title=Perrigo Closes Acquisition of Paddock Laboratories|url=https://storebrands.com/perrigo-closes-acquisition-paddock-laboratories|access-date=2021-07-22|website=Store Brands|language=en}}

In September 2012, Perrigo announced its intention to enter the animal wellness category by acquiring the assets of Sergeant's Pet Care Products, Inc., a privately held manufacturer of over-the-counter companion animal healthcare products.{{cite web|title=Perrigo Closes Acquisition Of Sergeant's Pet Care Products|url=http://perrigo.investorroom.com/2012-10-01-Perrigo-Closes-Acquisition-Of-Sergeants-Pet-Care-Products|website=Perrigo Company}}

On 11 February 2013, Perrigo announced the completion of the acquisition of Rosemont Pharmaceuticals Ltd., a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations.{{Cite web|url=https://investor.perrigo.com/2013-02-11-Perrigo-Company-Acquires-U.K.-based-Rosemont-Pharmaceuticals-Ltd.-For-Approximately-180-Million-Or-283-Million|title=Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million|website=Perrigo InvestorRoom}}

On 29 July 2013, the firm announced that it would acquire Élan, a pharmaceutical firm based in Dublin.{{cite web|url=https://www.handelsblatt.com/unternehmen/industrie/us-generikakonzern-perrigo-kauft-irische-pharmafirma-elan-/8563244.html|title=US-Generikakonzern: Perrigo kauft irische Pharmafirma Elan|agency=Reuters|date=29 July 2013|work=handelsblatt.com}}{{cite web|url=https://www.theguardian.com/business/2013/jul/29/us-drugmaker-perrigo-buy-elan|title=This page has been removed - News - The Guardian|work=the Guardian}} The Élan acquisition enabled Perrigo to reincorporate as an Irish company using Élan's headquarters (although the executive offices remained in Allegan), lowering its effective tax rate (called a tax inversion).{{cite news|url=https://www.bostonglobe.com/business/2013/07/29/perrigo-buy-elan-for-seeks-tax-savings/zefyefdUwJVDLG7ciScqtK/story.html|title=Perrigo to buy Elan, reincorporate in Ireland|author=Pogatchnik, Shawn|newspaper=Boston Globe|date=29 July 2013|access-date=20 January 2015}}

In November 2014, Perrigo announced it had agreed to buy Belgian health-products provider Omega Pharma approximately $4.5 billion (€3.6 billion).{{cite news| url=https://www.bloomberg.com/news/2014-11-06/perrigo-to-buy-omega-pharma-of-belgium-for-4-5-billion.html | work=Bloomberg | first=David | last=Risser | title=Perrigo to Buy Omega Pharma of Belgium for $4.5 Billion | date=6 November 2014}}{{cite news| url=http://www.standaard.be/cnt/dmf20141106_01361815 | work=De Standaard| title=Belgian newspaper De standaard reports Perrigo to Buy Omega Pharma for €3.6 Billion | date=6 November 2014}} The transaction was completed in March 2015.{{cite news |title=Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company |url=http://www.prnewswire.com/news-releases/perrigo-company-plc-completes-acquisition-of-omega-pharma-invest-nv-creating-a-top-five-global-otc-company-300057595.html |date=30 March 2015 |access-date=1 July 2015 |agency=PR Newswire |publisher=PR Newswire Association LLC }}

In August 2016, the company announced it would acquire US national distributor of over-the-counter medicines, Geiss, Destin & Dunn.{{Cite web|url=https://www.fiercepharma.com/pharma/struggling-perrigo-inks-deal-agreement-for-ga-based-distributor|title=Struggling Perrigo inks deal agreement for GA-based distributor|website=FiercePharma|date=17 August 2016 }}

In May 2019, Perrigo announced it would acquire Ranir Global Holdings LLC, boosting its oral self-care offering, with the transaction valued at $750 million.{{cite web|url=https://www.biospace.com/article/perrigo-to-expand-into-adjacent-self-care-category-by-acquiring-ranir-global-holdings-llc-the-leading-global-private-label-supplier-of-oral-self-care-products/|title=Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products|website=BioSpace}}

In February 2020, announced that it has reached an agreement to acquire the oral care assets of High Ridge Brands for $113 million.{{Cite web|url=https://www.biospace.com/article/perrigo-to-acquire-oral-care-assets-of-high-ridge-brands/|title=Perrigo To Acquire Oral Care Assets Of High Ridge Brands|website=BioSpace|language=en-US|access-date=2020-02-25}}{{Cite news|url=https://www.reuters.com/article/brief-perrigo-to-acquire-oral-care-asset-idUSASA00EQ3|title=BRIEF-Perrigo To Acquire Oral Care Assets Of High Ridge Brands|date=2020-02-24|work=Reuters|access-date=2020-03-19|language=en}}{{Cite web|url=https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/perrigo-to-acquire-oral-care-assets-of-high-ridge-brands-for-113m-57247463|title=Perrigo to acquire oral care assets of High Ridge Brands for $113M|website=www.spglobal.com|language=en-us|access-date=2020-03-19}}

In March 2021, Perrigo confirmed it would sell off its generics business to Altaris Capital Partners for $1.55 billion.{{Cite news|url=https://www.reuters.com/article/us-perrigo-company-divestiture-idUSKCN2AT2B0|title=Perrigo to sell generic drugs business for $1.55 billion|newspaper=Reuters|date=1 March 2021|via=www.reuters.com}} In September, the business announced it would acquire HRA Pharma from investment firms Astorg and Goldman Sachs Asset Management for $2.1 billion,{{Cite web|url=https://www.reuters.com/article/hra-pharma-m-a-perrigo-company/perrigo-to-buy-hra-pharma-in-2-1-billion-deal-to-expand-self-care-portfolio-idUSKBN2G4116|title = Perrigo to buy HRA Pharma in $2.1 BLN deal to expand self-care portfolio| website=Reuters |date = 8 September 2021}} and completed the acquisition in April 2022.[https://investor.perrigo.com/2022-05-02-PERRIGO-COMPLETES-THE-ACQUISITION-OF-HRA-PHARMA Perrigo Completes the Acquisition of HRA Pharma]

=Acquisition history=

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Perrigo (Founded as L. Perrigo Company, 1887)
Agis Industries Ltd (Acq 2005)
Galpharm International (Acq 2008)
J.B. Laboratories (Acq 2008)
Laboratorios Diba S.A. (Acq 2008)
Unico Holdings (Acq 2008)
Orion Laboratories Pty Ltd (Acq 2010)
PBM Holdings Inc (Acq 2010)
Paddock Laboratories Inc (Acq 2011)
Sergeant's Pet Care Products Inc (Acq 2012)
Rosemont Pharmaceuticals Ltd (Acq 2013)
Élan (Acq 2013)
Omega Pharma (Acq 2015)
Geiss, Destin & Dunn (Acq 2016)
Proteon Therapeutics (Acq 2016)
Ranir Global Holdings LLC (Acq 2019)
HRA Pharma (Héra SAS) (Acq 2022)

Segments

The company operates in three segments; Consumer Self-care Americas, Rx Pharmaceuticals, and Consumer Self-Care International. The Consumer Self-care Americas segment produces over-the-counter pharmaceutical and nutritional products in the United States and the United Kingdom. This segment offers analgesic, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, first aid, antacids, hemorrhoidal remedies, motion sickness, sleep aid products, feminine hygiene products, vitamin, and nutritional supplement products.{{Citation needed|date=July 2021}}

The Rx Pharmaceuticals segment produces generic prescription drugs in the United States. This segment provides creams, ointments, lotions, gels, and solutions, as well as nasal sprays, foams, and transdermal devices. Believing that Rx business has the potential to realize greater value outside of Perrigo, board okays separation of prescription pharma business on 9 August 2018.{{Cite news|url=https://www.reuters.com/article/us-perrigo-company-divestiture/perrigo-board-okays-separation-of-prescription-pharma-business-idUSKBN1KU0F9|title=Perrigo board okays separation of prescription pharma business|author=Reuters Editorial|work=U.S.|access-date=2018-08-09|language=en-US}}

The Consumer Self-Care International (CSCI) segment develops, manufactures, markets, and distributes well-known European self-care brands in the natural health and vitamins, cough, cold and allergy, oral care, smoking cessation, personal care and derma-therapeutics and lifestyle categories.